Immunome, Inc. (IMNM) Stock Grade

About Immunome, Inc.'s fundamentals

Immunome is a biotechnology company with a market capitalization of $1.9 billion that is currently unprofitable, posting a net loss in its latest annual statement with a net margin of -3060.0%. The company experienced significant revenue contraction, declining 23.2% year-over-year, indicating reduced commercial traction or sales activity. As a loss-making biotech firm, traditional valuation metrics like P/E ratio and return on equity are not applicable, and the company does not pay a dividend. This financial profile is typical of early-stage biotechnology companies investing heavily in research and development, though the substantial revenue decline warrants attention to the company's operational and clinical progress.